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Background: Rett syndrome (RTT) is an X linked neuro-developmental disorder affecting mostly girls.
Mutations in the coding region of MECP2 are found in 80% of classic RTT patients. Until recently, the
region encoding MECP2 was believed to comprise exons 2, 3, and 4 with the ATG start site located at the
end of exon 2 (MeCP2_e2).
Methods: Recent reports of another mRNA transcript transcribed from exon 1 (MeCP2_e1) prompted us to
screen exon 1 among RNA samples from 20 females with classic or atypical RTT.
Results: A previously reported 11 base pair deletion in exon 1 was detected in one subject with a milder
phenotype. Although RNA expression for both protein isoforms was detected from the mutant allele,
evaluation of MeCP2 protein in uncultured patient lymphocytes by immunocytochemistry revealed that
MeCP2 protein production was restricted to only 74–76% of lymphocytes. X chromosome inactivation
studies of genomic DNA revealed similar XCI ratios at the HUMARA locus (73:27 with HpaII and 74:26
with McrBC). We have demonstrated that translation but not transcription of the MeCP2_e2 isoform is
ablated by the 11 nucleotide deletion, 103 nucleotides upstream of the e2 translation start site.
Conclusions: These findings reveal that nucleotides within the deleted sequence in the 59-UTR of the
MeCP2_e2 transcript, while not required for transcription, are essential for translation.
R
TT syndrome (RTT) is a rare neuro-developmental
disorder affecting 1 in 10 000 girls and is mostly caused
by mutations in the X linked methyl CpG binding
protein 2 gene (MECP2), which is subject to X inactivation.1–3
Until recently, its protein coding region was believed to be
restricted to sequence within exons 2, 3, and 4 with the
translational start site positioned near the 39 end of exon 2.
Reports in 2004 of an alternate mRNA transcript arising from
exon 1, which is alternately spliced to exons 3 and 4, reveal a
higher level of complexity than was previously appreciated.
The protein isoform arising from exon 1 has been designated
MeCP2_e1 (e1), while the originally defined protein isoform
translated from exon 2 is now designated MeCP2_e2 (e2).
Further, expression levels of the MeCP2_e1 mRNA transcript
and protein isoform are much higher in brain than the
expression levels of MeCP2_e2 mRNA transcript and its
corresponding protein isoform.4 5
Mutations in exons 3 and 4 are detected in 80% of patients
with clinically diagnosed classic RTT and in a lower
proportion of atypical RTT cases.6 7 To date mutations have
not been detected in exon 2, although a limited number of
RTT causing mutations in exon 1 have now been reported.5 8 9
Using primers in exons 1 and 3, we screened RNA prepared
from fresh lymphocytes from 20 RTT cases that had been
classified as either classic or atypical RTT within the
Australian Rett Syndrome Database10 and in whom earlier
mutation screening had yielded wild type results. In one
subject, we identified an 11 base pair deletion in exon 1 that
has been previously reported.8 9 The deletion lies in the AGG
repeat region of exon 1 and was confirmed by direct sequence
analysis of genomic DNA. Subsequent assessment of MeCP2
protein production in uncultured fresh lymphocytes by
immunocytochemical analysis revealed absence of detectable
immunostaining in 24–26% of cells. Since the deletion lies in
the 59-UTR region of e2, we hypothesised that expression of
the e2 RNA transcript may be disrupted. However, fragment
length analysis of amplified cDNA revealed all four tran-
scripts, two from the wild type allele and two from the
mutant allele. We validated our immunocytochemistry
results by quantitative assessment of the X inactivation ratio
at the HUMARA locus in DNA prepared from the same
uncultured patient cells and observed similar ratios of 73:27
with HpaII, and 74:26 with McrBC. Our observations suggest
that the nucleotides within the deleted sequence in the 59-




Molecular and immunocytochemical studies were conducted
on blood samples collected in tubes with ACD anti-coagulant
from 20 female patients with classic or atypical RTT identified
from the Australian Rett Syndrome Database and in whom
earlier sequencing and MLPA screening of exons 2, 3, and 4
had not revealed a mutation. Prior approval for the study had
been provided by the ethics committee of Princess Margaret
Hospital for Children, Perth. Clinical details of the second
case were provided from InterRett.11
DNA analysis
DNA was extracted from 1200 ml of blood using the Puregene
DNA extraction kit (Gentra Systems, Minneapolis, MN)
according to the manufacturer’s instructions. PCR analysis
was performed on 50 ng of DNA as described previously.12
mRNA analysis
Total RNA was extracted from 1200 ml of blood using the
Purescript RNA extraction kit (Gentra Systems) as per the
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manufacturer’s instructions. RT-PCR was performed on RNA
using the Titan one step RT-PCR kit (Roche Applied Science,
Castle Hill, NSW, Australia). In brief, 50 ng of RNA was
added to the RT-PCR mix containing dNTPs (10 mM), DTT
(125 mM), 56RT-PCR buffer, 50 ng each of forward (Ex1F2)
and reverse (Ex4R2) primers in exons 1 and 4, respectively,
and 1 U of enzyme (refer to table 1 for primer sequences).
After reverse transcription at 48 C˚ (30 min), the samples
were PCR amplified at an annealing temperature of 61 C˚ for
25 cycles. A 1 ml aliquot of the product from the primary PCR
was further amplified in a semi-nested PCR reaction using
primers in exon 1 (Ex1F2) and exon 3 (Ex3R2) and Tth
polymerase enzyme at an annealing temperature of 61 C˚ for
25 cycles. PCR products were assessed visually by electro-
phoresis on a 2% agarose gel.
Purification and sequencing of PCR products
PCR products were purified using the Qiaquick PCR
purification kit or gel extracted using the Qiaex II Gel
purification kit (Qiagen, Doncaster, Vic, Australia). The
purified products were sequenced using BigDye terminator
chemistry version 3.1 on an ABI 3730 (Applied Biosystems,
Foster City, CA, USA). Sequence chromatograms were
analysed using Chromas software (Technelysium, Tewantin,
Qld, Australia).
Immunocytochemical analysis
Buffy coat was separated from blood samples within 24 h of
venesection and frozen in DMSO with liquid nitrogen.
Samples from healthy individuals were used as normal
(positive staining) controls for immunostaining in each
assay. For every analysis, autofluorescence controls (contain-
ing no primary or secondary antibody) and mock controls
(containing no primary antibody but stained with secondary
antibody) were set up as negative controls from each sample.
When required for immunochemical studies, frozen cells
from a patient and at least one healthy individual were
thawed simultaneously and resuspended in RBC lysis buffer
for 10 min. The residual white cell pellet was collected by
centrifugation and fixed with 5% formaldehyde in PBS. Cells
were permeabilised for 10 min in PBS containing 0.1% Triton
X-100 and blocked in PBS containing 1% BSA and 2% FCS
before incubation with primary antibody (N-terminal anti-
body generated using a peptide of amino acids 9–27 of
human MeCP2 and C-terminal antibody to amino acids 329–
348 of human MeCP2, amino acid positions with reference to
the e2 protein isoform) in a dilution of 1:100 in PBS
containing 1% BSA, 2% FCS, and 0.1% Triton X for 45 min
at room temperature. After three washes in PBS containing
1% BSA and 2% FCS, cells were incubated with a secondary
goat anti-rabbit antibody conjugated with FITC (Jackson
Immunochemicals, West Grove, PA, USA) in a dilution of
1:100 in permeabilisation buffer containing 1% BSA and 2%
FCS for 30 min at room temperature. The cells were then
washed three times and cytospun onto slides. Slides were
mounted in DAPI and cells were counted and analysed under
a fluorescent microscope (Olympus, Melville, NY, USA).
Fragment length analysis
Fragment length analysis was performed on the products of
RT-PCR with FAM labelled forward primer 1F2 and reverse
primer 3R2 (table 1). Products were analysed using GeneScan
software (Applied Biosystems).
X chromosome inactivation studies
X chromosome inactivation analysis was conducted on 2 mg
of DNA sample with two different methylation sensitive
restriction enzymes. In one tube DNA was digested with
HpaII, which digests unmethylated DNA, and in the other
with McrBC, which digests methylated DNA. The digested
DNA was amplified using previously published labelled
primers for the androgen receptor gene and analysed using
GeneScan software according to previously published proto-
cols.13 14 For quantification, the peak area underneath the
smaller allele was divided by the sum of the peak areas for
both alleles after correction.
Analysis of the MeCP2_e2 59-UTR
We analysed the secondary structure of the wild type and
mutant sequence of MeCP2_e2 59-UTR using the Mfold
program available from the Burnet Institute, Melbourne at
http://mfold.burnet.edu.au/. This program predicts optimal
and suboptimal secondary structures of RNA based on free
energy minimisation.15 The 170 nucleotide 59-UTR sequence
(GenBank accession number AY523575) up to the AUG start
codon and a sequence of 159 nucleotides (170 del 11)
depicting the deletion of 11 nucleotides in the 59-UTR were
folded using the default parameters. Planar tree graphs were
constructed for comparison of secondary structures.16
RESULTS
Proband
The proband was a female born by spontaneous vertex
delivery after a pregnancy complicated only by hypertension
requiring induction at term. The proband’s mother had
reported reduced fetal movements earlier in the pregnancy.
Birth weight was 3317 g (10th–50th percentiles) and head
circumference was 35 cm (50th percentile). The proband was
initially dusky with an Apgar score of 7 at 1 min. She was
breast fed but later experienced difficulty sucking a bottle.
She sat at age 5.5 months. Concerns about her develop-
ment emerged between 6 and 10 months. At 10 months she
was placid and bottom shuffling. Crawling began at
12 months. By 13 months she was pulling herself up on
furniture and eventually walked at 21 months.
The family were initially worried, both because of her
motor delay as well as her overall slowing down of
development. Around 18 months she appeared to be socially
disengaged and had autistic traits. She spoke her first words
at 18 months but at about 30 months (at which time she had
been speaking single words) her speech began to deteriorate.
Gradual loss of hand use and development of hand
stereotypies then emerged at 36 months. At the age of
13 years, she remains able to pick up a grape and finger feed.
Seizures, which started at around 3 years, have responded
partially to carbamazepine. Currently, she does not have
scoliosis but suffers from constipation, grinds her teeth, and
has periodic rapid breathing. At the age of 13 years she
remains independently mobile and is well nourished with no
growth or other major health problems. Her clinical features
are summarised in table 2 alongside the clinical features of
the first reported case5 notified to InterRett.17
Detection of an 11 nucleotide deletion
We determined the sequence of mRNA extracted from 20 RTT
patients (10 atypical, 10 classic) in whom mutation screening
of exons 2, 3, and 4 by sequencing and MLPA had yielded
Table 1 Sequences of primers used in reverse
transcription and PCR analysis
Name Sequence Location
1F2 59 -TAAAAGCCGTCCGGAAAAT Exon 1
3R2 59 -CTCAGCAGAGTGGTGGGCTGA Exon 3
4R2 59 -AGTTTGAAAGGCATCTTGAC Exon 4
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wild type results. In all patients, amplification with primers
in exon 1 and exon 3 yielded two bands, which were
confirmed by sequence analysis using forward and reverse
primers to be wild type e1 and e2 mRNA transcripts. In a
sample from one atypical RTT patient (212), a smaller band
was also observed, which upon sequencing revealed a
previously reported 11 nucleotide deletion in exon 1
(c.47_57del GCGAGGAGGAG) (fig 1A,B). Genomic DNA
obtained from the patient was assessed by sequencing and
the deletion was again detected in exon 1 (fig 1C,D).
Absence of MeCP2 in the peripheral lymphocytes
To investigate the effects of the 11 nucleotide deletion on
protein translation, peripheral lymphocytes from the patient
were analysed immunocytochemically with anti-MeCP2
antibodies directed against the N- and C-terminals which
detect both MeCP2 protein isoforms. Peripheral lymphocytes
from a normal subject were used as a positive control for the
assay (fig 2A–D, panels i and ii). FITC staining was not
detectable in cells from autofluorescence and mock controls
from the normal individual (fig 2A, i and ii and fig 2B, i and
ii) and patient 212 (fig 2A, iii and iv and fig 2B, iii and iv). We
noticed that cells positively stained with MeCP2 antibodies
show variable intensity of staining (fig 2C,D, i–iv). We
counted 250 cells from positive control slides stained with the
N-terminal antibody and found 99.2% of cells (lower end of
95% CI 97 to 99) staining positively (fig 2C, i and ii).
Similarly, from the positive control slides stained with the C-
terminal antibody (fig 2D, i and ii), we counted 289 cells and
found positive staining in 98.6% of cells (lower end of 95% CI
96 to 99). In cells from patient 212, a mixture of fluorescing
(positive, indicated by arrowheads) and non-fluorescing
(negative, indicated by arrows) cells were observed
(fig 2C,D, iii and iv), indicating, in our interpretation, loss
of both the MeCP2_e1 and MeCP2_e2 protein isoforms. We
counted 321 cells from slides stained with the antibody
against the N-terminal epitope (fig 2C, iii and iv) and found
positive staining in 76% of cells (95% CI 70 to 80). Similarly,
on slides stained with the C-terminal antibody (fig 2D, iii and
iv), 74% (95% CI 68 to 78) of 285 cells counted, stained
positively, with the remainder showing absence of staining.
cDNA fragment length analysis
Fragment length was analysed by GeneScan on the RT-PCR
products to confirm the presence of deletions in both the e1
and e2 transcripts (fig 1E). Four transcripts, two wild type
fragments (indicated by arrows in fig 1E) and two
corresponding mutant fragments that were 11 base pairs
shorter than the wild type lengths (indicated by asterisks in
fig 1E), were revealed and this confirmed the presence of two
RNA transcripts from the mutant allele.
X chromosome inactivation studies
Quantitative XCI results from the HpaII digest revealed a
ratio of 73:27. An independent parallel assay with McrBC
yielded a confirmatory ratio of 74:26.
Analysis of 59-UTR sequence
Since the 11 nucleotide deletion is upstream of the AUG start
codon for the e2 protein isoform, we examined its 59-UTR
sequence for features that could explain the influence of the
deletion on the initiation of translation. The Mfold program
Table 2 Comparative table of phenotypical features from two reported cases with exon 1 mutation
Patient 212 (Australian case)
Patient 052 (InterRett case published in
Mnatzakanian et al5)
Pregnancy
Maternal health Maternal hypertension requiring No problems
induction at term
Pregnancy duration 40 weeks 40 weeks
Birth and first week of life
Birth weight 3317 g 3430 g
Birth head circumference 35 cm Not available
APGAR at 1 min 7 9
First week of life No problems No problems
Early development
Parental comments about period up to 6 months Breast fed satisfactorily. Would not suck Vomited frequently
on a bottle
Parental comments about period from 6 Placid and rather slow. Wouldn’t crawl Unable to sit up unaided until 11 months.
to 10 months Continued to vomit often in the morning.
Age at independent walking 21 months 18 months
Age at use of words with meaning 18 months 18 months
Parental concerns
First concerns Reduced social engagement at 18 months Speech delay
First diagnosis Autism Autism
Age and year of clinical diagnosis of Rett syndrome 3 years (1994) 9 years (1985)
Features of regression
Level of speech prior to deterioration Single words 3 word sentences
Age at loss of speech 30 months 36 months
Nature of deterioration Gradual Gradual
Loss of hand use Yes Yes
Age at deterioration of hand use 36 months 48 months
Age at development of hand stereotypies 36 months 48 months
Current status
Age in 2005 13 years 28 years
Speech at present No No
Ability to walk Walks independently Walks independently
Ability to finger feed Yes Able to fill and use a spoon with help
Best level of hand use today Can pick up a grape and finger feed Can finger feed, picks up a grape, holds a glass
to drink, and points to sign/objects with palm
Other features
Presence of epilepsy Yes Yes mild, fully suppressed with Tegretol
Age at diagnosis of seizures 3 years 11 years
Presence of scoliosis No Yes
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predicted six secondary structures for the wild type 59-UTR
RNA sequence and 16 for the deletion mutant RNA. The five
most stable secondary structures for wild type sequence and
the mutant sequence are shown in fig 3A,B. The Gibbs free
energy of formation, which is approximated as a sum of
negative contributions from helices plus positive contribu-
tions from the loss of entropy when loops and bulges form,
ranged from 252.3 kcal/mol to 249.8 kcal/mol for the wild
type sequence and from 242.6 kcal/mol to 240.5 kcal/mol
for the deletion mutant. Structural analysis of the two
transcripts revealed that the mutant sequence formed a more
complicated secondary structure than the wild type sequence.
Tree graphs of the secondary structures revealed a consistent
Y shaped structure in the wild type sequence, whereas only
two out of the 16 predicted structures of the mutant sequence
(structure numbers 4 and 14, fig 3B, iv and v) had a Y shaped
tree graph similar to the wild type sequence. Inspection
revealed that the main stem of the Y shaped structure is
Figure 1 Sequence chromatograms and fragment length analysis. Numbers in the chromatograms correspond to c.DNA sequence for MeCP2_e1
with the A of ATG start site numbered as 1. Arrows marked with an asterisk indicate the exon/exon junction in RNA sequences shown in panels A and
B and exon/intron junction in DNA sequences shown in panels C and D. Nucleotides underlined in red are upstream of the deletion, while those in
black are downstream. The 11 nucleotide deletion is shown in the box in sequences from normal individuals. (A, B) Sequence chromatograms from the
RNA of a normal individual (A) and patient 212 (B). The nucleotides in the box in panel A were found to be deleted in the chromatogram obtained from
the RNA of patient 212 shown in panel B. (C, D) Sequence chromatograms from the DNA of a normal individual (C) and patient 212 (D). The deletion
is seen as a mixed chromatogram beneath the underlined sequence in the patient DNA in panel D. (E) Fragment length analysis of the mRNA
transcripts with GeneScan software. All four RNA transcripts, two arising from the normal allele (indicated by arrows) and two from the mutant allele
(indicated by asterisks), are clearly visible. The mutant RNA transcripts differ from the wild type RNA transcripts by 11 nucleotides.
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made of 10 uninterrupted stacked pairs with three GU
wobble bases in five out of six predicted structures for the
wild type sequences. In contrast, the main stem of the Y
shaped tree graph in structures 4 and 14 of mutant sequence
is made of four uninterrupted stacked pairs with no GU
wobble bases. In the wild type sequence, the double stranded
stem is interrupted by a multi-loop at one end consisting of
11–15 single stranded nucleotides and a bulge of five to nine
single stranded bases at the other end, but in the mutant
structures 4 and 14, the stem is interrupted by multi-loops at
both ends consisting of a maximum number of eight single
stranded nucleotides at one end and two at the other. The
multi-loop and bulge interrupting the stem in the wild type
structures have a GU wobble pair as the external closing pair
whereas no such closing pair was observed in the multi-loops
interrupting the stem in the mutant sequence.
DISCUSSION
We have identified a case with an exon 1 mutation, which
has been previously reported, by screening samples from 20
mutation negative classic and atypical RTT patients identified
from the Australian Rett Syndrome Database.10 The mutation
is an 11 base pair deletion 46 bases downstream from the
start codon in exon 1 (c.47_57del GCGAGGAGGAG). The
deletion results in a frame shift and generates a missense
protein sequence after amino acid position 15, which stops
after amino acid position 36 in the MeCP2_e1 protein
isoform. In contrast, the reading frame of the MeCP2_e2
protein isoform is unaffected, as the 11 nucleotide deletion is
positioned within the 59-UTR starting 103 nucleotides
upstream of the e2 protein translation initiation site.
Although the e1 protein isoform would be absent from a
proportion of cells in this patient, we expected positive
immunostaining in all lymphocytes due to the presence of
the intact e2 protein isoform in all cells, which in
lymphocytes is presumably much more abundantly produced
than the e1 protein isoform, in line with the observed RNA
levels.5 However, evaluation of MeCP2 protein in uncultured
peripheral lymphocytes from the patient with anti-MeCP2
antibodies directed against both the N- and C-terminal
epitopes, demonstrated no discernible protein in 24% (95% CI
19 to 29) and 26% (95% CI 21 to 31) of cells, respectively,
which is significantly elevated compared with 0.8–1.4% (95%
CI 0.2 to 3) of cells in the positive control slides that failed to
stain.
To investigate further the reason for the absence of protein
in cells, we looked for evidence of a shorter MeCP2_e2 mRNA
species, which, if present, would indicate transcription from
the mutant allele. Demonstration of the mutant RNA
transcripts for both isoforms (indicated by asterisks in
Figure 2 Immunofluorescence analysis of peripheral blood lymphocytes. Panels i and ii show cells from a normal individual immunostained with DAPI
(blue) and FITC (green), respectively. Panels iii and iv show cells from patient 212 stained with DAPI in blue and FITC in green, respectively. Panel A
shows autofluorescent controls where no primary or secondary antibody was used during staining. Panel B shows FITC only staining controls, where
cells were stained with the secondary antibody (mouse anti-rabbit FITC) alone. Note green staining of cells is not detectable in the negative controls
from a normal subject (i and ii) and patient 212 (iii and iv) shown in panels A and B. Cells stained with the antibody against the N-terminal epitope are
shown in panel C and cells stained with the antibody against the C-terminal epitope are shown in panel D. All cells from a normal individual show
positive green staining with antibodies against the N-terminal and C-terminal shown in panels i and ii. Note the mixture of green staining positives
(indicated by arrowheads) and non-staining negatives (indicated by arrows) in cells from the patient shown in panels iii and iv. In patient cells, 76% of
cells stained positive with the antibody against the N-terminal of MeCP2 and 74% stained positive with the antibody against the C-terminal of MeCP2.
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fig 1E) in the patient sample, from which RNA was extracted
24 h after venesection, suggests that RNA instability is very
unlikely to be responsible for the absence of protein.
To assess the validity of our immunostaining results, we
sought additional indirect evidence from quantitative XCI.
Two independent assays at the HUMARA locus yielded XCI
ratios that closely matched our observation of 74–76% of cells
staining with antibodies against MeCP2 protein. Our
immunostaining and X inactivation findings reveal that the
wild type allele is active in the majority of patient
lymphocytes, although it is appreciated that the X inactiva-
tion ratio in peripheral blood lymphocytes may not reflect the
ratio in brain tissue.
It is known that the 59-UTR plays an important role in
tissue specific protein translation and in some instances has
been shown to regulate the level of protein translation
without affecting transcription.18–21 From observations in a
mouse model, which revealed that even mild overproduction
of MeCP2 protein may cause neurological deficits,22 it appears
that MeCP2_e2 protein levels in vivo are tightly regulated. It
is known that the upstream AUG in exon 1 interferes with
the translation of MeCP2_e2 protein isoform.4 Since the
translation efficiency of a transcript is also affected by the
length and secondary structure of its 59-UTR,23 24 we
considered the possibility that the upstream AUG combined
with altered RNA secondary structure may adversely affect
translation24 25 and examined the predicted secondary struc-
tures arising from mutant 59-UTR compared with those
predicted for the wild type. The Gibbs free energy of
formation for the predicted secondary structures of the wild
type and mutant 59-UTRs indicates that both are stable,
which strongly suggests that additional factors are required
for initiation of translation.24 26 27 It is interesting to note that
part of the deleted sequence (GCGAGGAGGAG) bears
similarity to the Shine-Dalgarno sequence (AGGAGG), which
is important for initiation of translation in prokaryotes28 29
and archaea,30 although its significance in mammalian cells is
unknown. The deleted sequence also participates in the
formation of a nine nucleotide repeat GAGGAGGAG around
GC (GAGGAGGAGGCGAGGAGGAG). Such repeats in the 59-
UTR could provide binding sites for proteins involved in
translation.24 The tree diagrams clarify the general shape of
the predicted folds and reveal that five out of the six
predicted structures for the wild type sequence retain a
similar overall structure, consisting of a long double stranded
stem interrupted by single stranded loops. The deleted
sequence contributes to the double stranded stem in all the
predicted structures for the wild type sequence. This double
stranded stem is shortened upon deletion of the 11 bases
causing a change in secondary structure. Whether such
subtle differences in secondary structure are sufficient to
cause ablation of MeCP2_e2 protein translation remains to be
determined experimentally.
Alternatively, it is possible that the e1 protein isoform is
abundantly produced in lymphocytes, while the e2 protein
isoform remains poorly translated despite higher levels of e2
mRNA transcript, because of interference from the upstream
AUG in exon 1. It has been shown in vitro that the start
codon in exon 1 interferes with the initiation of translation at
the start site in exon 2, resulting in low levels of e2 protein
isoform.4 Furthermore, the levels of native e2 protein isoform
were noted to be 10 times lower than the levels of native e1
protein isoform in the brain tissue. As the deletion does not
disrupt the upstream AUG in our subject, it seems likely that
the phenomenon of translational interference has remained
intact and, in combination with the RNA secondary
structural changes induced by the mutation, results in a
major reduction in the levels of the e2 protein isoform.
Additional in vivo studies designed to determine endogenous
levels of e1 and e2 protein isoforms in lymphocytes and other
tissues would indicate whether the upstream AUG interferes
with translation from the MeCP2_e2 start site in these tissues.
Thus, at this stage, the exact molecular mechanism leading
to the unexpected absence of MeCP2_e2 protein isoform in a
i ii iii iv v
viviiiiii
∆G = –52.3 ∆G = –51.8 ∆G = –51.7 ∆G = –51.3 ∆G = –50.8
Structure 4
Structure 14
∆G = –40.7∆G = –41.4∆G = –41.9∆G = –42.3∆G = –42.6
A
B
Figure 3 Predicted secondary structure analysis of wild type and mutant 59-UTR of MeCP2_e2 using Mfold. (A) The five most stable secondary
structure predictions of the wild type MeCP2_e2 59-UTRs are shown in panels i–v. (B) Panels i–iv show the four most stable secondary structures
predicted for the mutant MeCP2_e2 59-UTR, including structure 4. Panel v shows predicted structure 14. Simplified tree graphs drawn for each structure
are depicted as insets. The Y shaped structure is indicated in bold within the insets. Only structures 4 and 14 of the mutant sequence show similarity to
the tree graphs of the wild type structures with subtle differences that are discussed in the text.
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proportion of cells in this patient remains undefined. It
cannot be explained on the basis of protein instability, as the
mutation is upstream of the coding region of the e2 RNA
transcript. Nonsense mediated decay is ruled out by our
observation of the retention of the mutant e1 RNA transcript
containing the premature termination codon, as well as the
mutant e2 RNA transcript with the normal coding sequence.
Combining the results of our analysis of the secondary
structures of mutant and wild type 59-UTR and a previous
study on upstream AUG in exon 14 suggests that protein
translation from the e2 mRNA transcript is regulated in part
by the upstream AUG and factors binding within or to
sequences overlapping the 11 deleted nucleotides in its 59-
UTR, or to secondary structures induced by the deleted
sequence. Further experiments designed to elucidate these
binding factors should yield some insights into the exact
mechanism of regulation. Nevertheless, our protein and RNA
level analysis of this non-coding mutation extends knowl-
edge of the biological consequences of this particular
mutation. The splice site mutation reported by Amir et al9
also has the potential to disrupt both protein isoforms,
although an aberrantly spliced RNA transcript was not
observed in that study. Importantly, our findings do not
support a gathering view that the mutation we have studied
ablates only the MeCP2_e1 protein isoform and that an RTT-
like phenotype may occur in the presence of a normal
MeCP2_e2 protein isoform.8
Comparison of the clinical features of the Australian and
the Canadian case, which was originally reported by
Mnatzakanian et al5 and subsequently notified to the
international InterRett database,17 reveals some interesting
similarities. Although the two subjects have different exon 1
mutations at the genomic DNA level, because of tri-
nucleotide repeats in the region of deletions, the 11
nucleotide deletion reported in Mnatzakanian et al results
in the generation of the same mutant DNA and RNA
sequence as in our subject. Consequently, both the mutations
generate identical missense proteins that then terminate after
amino acid 36. Both subjects have a phenotype that is slightly
milder than usual. Regression in both subjects occurred later
than normally expected and motor function (including hand
function) was better than average for subjects with classic
Rett syndrome. The Australian patient is 15 years younger
than the Canadian subject, who, at 28 years, has a slightly
lower level of mobility. Quantitative X inactivation studies on
the samples from the Canadian case revealed a ratio of 64:46
(personal communication, Dr Patrick MacLeod). We note
that the atypical case reported by Amir et al,9 who has the
same 11 base pair deletion as our case, had random X
inactivation although no additional clinical details were
provided. Until more clinical data are published on these
exon 1 cases, it is not possible to comment further on the
most likely biological basis of the observed phenotypes, in
particular whether they reflect patterns of X inactivation,
bearing in mind the immunostaining finding in the
Australian case that reveals the wild type allele is active in
the majority of cells, a finding that is consistent with the
observed milder clinical features in this child. Alternatively,
this particular mutation may be characteristically milder in
its clinical consequences, as has been found for mutations
such as R133C and R306C.31 32
In conclusion, as well as revealing the biological impor-
tance of the deleted non-coding region of RNA for protein
translation, our findings confirm the emerging consensus
that mutations in exon 1 are responsible for only a minority
of RTT cases, which is not surprising given the small
proportion of nucleotides contributed by exon 1 to the gene’s
total coding sequence. Pooling the findings among our 20
cases with the earlier published findings from exon 1
screening reveals that a total of seven exon 1 mutations
have been detected among 209 mutation negative RTT
patients (2/19 patients in Mnatzakanian et al,3 2/63 in Amir
et al,9 0/97 in Evans et al, 2/10 in Ravn et al,8 and 1/20 in this
study). At a practical level, this permits an estimate to be
made of the prevalence of exon 1 mutations among mutation
negative RTT cases of 3.3% (95% CI 1.6 to 6.7). As mutation
negative RTT patients represent approximately one in five of
all cases, the overall contribution of exon 1 mutations to the
occurrence of RTT is less than 1%.
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